Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Pterostilbene Improves Mitochondrial Quality to Delay Dermal
2026-07-17
Zhou et al. (2025) demonstrate that pterostilbene counters senescence in human dermal fibroblasts by enhancing mitochondrial quality control, specifically through increased mitophagy. This mechanistic insight supports mitochondrial maintenance as a promising strategy to mitigate both intrinsic and extrinsic skin aging.
-
Angiotensin II: Strategic Leverage for Translational Vascula
2026-07-17
This article explores the mechanistic, experimental, and translational significance of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) in cardiovascular research. By blending molecular insight with workflow guidance, it provides researchers with a competitive edge for modeling hypertension, vascular remodeling, and emerging cross-domain questions such as peptide-virus interactions. The discussion draws on recent peer-reviewed findings, established protocols, and workflow optimization, while highlighting the distinctive value of APExBIO's Angiotensin II for reproducibility and translational impact.
-
AEBSF.HCl: Strategic Protease Inhibition in Necroptosis and
2026-07-16
This article provides translational researchers with a mechanistic and strategic guide to deploying AEBSF.HCl (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride) in the study of necroptosis, amyloid precursor protein processing, and cell death. Drawing on recent findings that clarify the central role of lysosomal membrane permeabilization and cathepsin activity in regulated cell death, we outline actionable protocols, competitive insights, and forward-looking clinical relevance. The discussion is grounded in both primary research and advanced application guides, highlighting how APExBIO’s AEBSF.HCl offers tools and confidence for next-generation cell death and neurodegeneration research.
-
WEHI-539: Precision BCL-XL Inhibitor for Apoptosis Research
2026-07-16
WEHI-539 stands out as a benchmark BCL-XL inhibitor, enabling selective and potent induction of apoptosis in BCL-XL-dependent models. This guide delivers actionable protocols, troubleshooting strategies, and advanced use-cases for dissecting apoptotic pathways and addressing chemoresistance in cancer stem cells.
-
Oteseconazole (VT-1161): Next-Gen Antifungal Strategies for
2026-07-15
This thought-leadership article explores the mechanistic underpinnings and translational potential of Oteseconazole (VT-1161), a selective tetrazole CYP51 inhibitor for Candida infections. Integrating recent breakthroughs in antifungal drug design and clinical workflow optimization, it addresses the evolving landscape of resistance, safety, and efficacy—offering strategic guidance for researchers at the forefront of antifungal discovery and development.
-
Fluo-4 AM in High-Fidelity Calcium Imaging: Mechanisms and A
2026-07-15
Explore how Fluo-4 AM, a gold-standard fluorescent calcium indicator, enables ultra-precise intracellular calcium concentration measurement. This article uniquely dissects the mechanistic foundations and practical assay advantages of Fluo-4 AM, informed by the latest hybrid photoreceptor research.
-
AZD3463: Advanced ALK/IGF1R Inhibitor Workflows for Cancer R
2026-07-14
AZD3463 empowers researchers with robust ALK/IGF1R inhibition, enabling reproducible neuroblastoma models—even those harboring resistance mutations. This guide delivers actionable protocols, troubleshooting strategies, and insights that maximize AZD3463's impact in both monotherapy and combination regimens.
-
Angiotensin II: Mechanistic Insight and Translational Levera
2026-07-14
This article delivers a strategic, evidence-driven exploration of Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) as a linchpin in vascular biology and disease modeling. Blending rigorous mechanistic insight with actionable guidance, we bridge hypertension, cardiovascular remodeling, and emerging cross-domain considerations such as viral pathogenesis, with a forward-looking perspective tailored for translational researchers.
-
Angiotensin 1/2 (5-7): Applied Workflows in RAS and Viral Re
2026-07-13
Angiotensin 1/2 (5-7) bridges cardiovascular and viral pathogenesis studies, empowering researchers with reproducible, high-fidelity assays for both blood pressure regulation and SARS-CoV-2 spike protein binding. This guide details optimized experimental workflows, advanced use-cases, and troubleshooting strategies for leveraging this versatile peptide in renin-angiotensin system research.
-
Graphene-Mediated FIR Induces Apoptosis in Melanoma Cells
2026-07-13
This study demonstrates that graphene-mediated far-infrared radiation (FIR) effectively suppresses malignant melanoma by inducing apoptosis, cell cycle arrest, and hypoxic stress. Use of selective caspase inhibitors, including Z-LEHD-FMK, validates the centrality of caspase-dependent mitochondrial apoptosis pathways in the anti-tumor effects of FIR.
-
KPT-330 (Selinexor): Redefining Nuclear Export in Cancer Mod
2026-07-12
Explore how KPT-330 (Selinexor), a selective CRM1 inhibitor from APExBIO, empowers translational researchers to target nuclear export and overcome drug resistance in cancer. This article blends mechanistic insight with hands-on protocol guidance and examines how XPO1 inhibition can synergize with platinum chemotherapy, setting a new paradigm for preclinical and translational oncology.
-
Cy5.5 NHS Ester (Non-sulfonated): Precision Labeling for In
2026-07-10
Cy5.5 NHS ester (non-sulfonated) empowers researchers to achieve highly sensitive, stable, and deep-tissue labeling of proteins and nanoparticles for in vivo imaging. This guide demystifies advanced workflows, troubleshooting, and translational use-cases—drawing direct links to non-invasive neuromodulation and tumor visualization breakthroughs.
-
HyperScribe T7 High Yield Cy5 RNA Labeling Kit in Probe Desi
2026-07-09
The HyperScribe T7 High Yield Cy5 RNA Labeling Kit streamlines customizable fluorescent RNA probe generation for sensitive in situ and Northern blot applications. Its tunable Cy5-UTP incorporation and high-yield chemistry solve key challenges in probe sensitivity, reproducibility, and workflow efficiency.
-
Cellular Senescence Genes as Diagnostic Biomarkers in AAA
2026-07-09
This study identifies key cellular senescence-related genes, ETS1 and ITPR3, as robust biomarkers for the early diagnosis of abdominal aortic aneurysm (AAA). Leveraging machine learning and multi-cohort validation, the research clarifies the molecular connection between vascular senescence and AAA progression, offering new avenues for noninvasive diagnostics and targeted intervention.
-
Cy5 maleimide (non-sulfonated): Technical Guide and Best Pra
2026-07-08
Cy5 maleimide (non-sulfonated) enables site-specific fluorescent labeling of proteins and peptides containing accessible cysteine residues, supporting sensitive detection in fluorescence imaging and assay workflows. It is unsuitable for biomolecules lacking thiol groups or for protocols requiring dyes with high aqueous solubility.